Abstract
Psoriasis is a common inflammatory skin disease, and conflicting data have been published about osteoporosis and bone turnover markers in patients with psoriatic arthritis. The aim of this study was to assess bone mineral density (BMD) and bone turnover markers in psoriatic patients with and without peripheral arthritis and to investigate the relationship between clinical parameters and markers of bone turnover. Forty-seven patients (24 women, 23 men) with psoriasis were included to the study. Demographic data and clinical characteristics were recorded. Erythrocyte sedimentation rate and C-reactive protein were assessed as disease activity parameters. BMD was determined for lumbar spine and total hip by dual X-ray absorptiometry (DXA). Serum Ca, P, alkalen phosphatase (ALP), and serum type I collagen cross-linked C telopeptide (CTX) were measured as bone turnover markers in all patients. The patients were divided into two groups according to their peripheral arthritis status. The clinical and laboratory variables, as well as bone mass status of the groups, were compared with each other. Eighteen patients had peripheral arthritis. All the female patients were premenopausal. None of the patients had radiologically assessed axial involvement. There was no significant difference between the BMD levels of psoriatic patients with and without arthropathy. One patient (5%) had osteoporosis, and nine (50%) patients had osteopenia in arthritic group, while eight (27.5%) patients had osteopenia in patients without arthritis. Serum CTX, ALP, Ca, and P levels were not significantly different in arthritic than in non-arthritic patients (p > 0.05). In patients with psoriatic arthritis, the duration of arthritis was negatively correlated with BMD values of lumbar spine and total femur and serum CTX levels, suggesting an association of increased demineralization with the duration of joint disease. In conclusion, psoriatic patients with peripheral arthritis with longer duration of joint disease may be at a risk for osteoporosis, which can require preventative treatment efforts.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course and outcome. Ann Rheum Dis 64(Suppl II,ii):14–18
Gladman DD, Rahman P (2001) Psoriatic arthritis. In: Ruddy S, Harris ED, Sledge CB, Budd RC, Sergent JS (eds) Textbook of rheumatology, 5th edn. Saunders, Philadelphia, pp 1071–1079
Shibuya K, Hagino H, Morio Y, Teshima R (2002) Cross-sectional and longitudinal study of osteoporosis in patients with rheumatoid arthritis. Clin Rheumatol 21:150–158
MacDonald AG, Birkinshaw G, Durham B, Bucknall RC, Fraser WD (1997) Biochemical markers of bone turnover in seronegative spondyloarthropathies: Relationship to disease activity. Br J Rheumatol 36:50–53
Borman P, Bodur H, Bingöl N, Bingöl S, Bostan EE (2001) Bone mineral density and bone turnover markers in a group of male ankylosing spondylitis patients: relationship to disease activity. J Clin Rheumatol 7:315–321
Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlar M et al (2002) Ankylosing spondylitis, psoriatic arthritis and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 29:1430–1436
Magaro M, Altomonte L, Mirone L, Zoli A, Tricerri A (1989) Clin Rheumatol 8:494–498
Harrison BJ, Hutchinson CE, Adams J, Bruce IN, Herrick AL (2002) Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. Ann Rheum Dis 61:1007–1011
Millard TP, Antoniades L, Evans AV, Smith HR, Spector TD, Barker JNWN (2001) Bone mineral density of patients with chronic plaque psoriasis. Exp Dermatol 26:446–448
Dheda K, Cassim B, Patel N, Mody GM (2004) A comparison of bone mineral density in Indians with psoriatic polyarthritis and healthy Indian volunteers. Clin Rheumatol 23:89
Nymann P, Kollerup G, Jemec GBE, Grossman E (1996) Decreased bone mineral density in patients with pustulosis palmaris et plantaris. Dermatology 192:307–311
Frediani B, Allegri A, Falsetti P, Storri L, Bisogno S et al (2001) Bone mineral density in patients with psoriatic arthritis. J Rheumatol 28:138–143
Fredriksson T, Pettersson U (1978) Severe psoriasis: oral therapy with a new retinoid. Dermatologica 157:238–244
Kanis JA, Melton LJ, Christiansen C et al (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:1137–1141
Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM (2003) Mechanisms of TNF-alpha and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111:821–831
Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342
Nolla JM, Fiter J, Rozadilla A et al (1999) Bone mineral density in patients with peripheral psoriatic arthritis. Rev Rheum Engl Ed 66:457–461
Hein G, Abendroth K, Muller A, Wessel S (1991) Studies on psoriatic osteopathy. Clin Rheumatol 10:13–17
Cranney AB, McKendry RJ, Wells GA, Ooi DS, Kanigsberg ND et al (2001) The effect of low dose methotrexate on bone density. J Rheumatol 28:2395–2399
Di Giovanna JJ, Solitto RB, Abangan DL, Steinberg SM, Reynolds JC (1995) Osteoporosis is a toxic effect of long term etretinate therapy. Arch Dermatol 131:1263–1267
Margolis DJ (1996) Osteoporosis and long term etretinate therapy (letter). Arch Dermatol 132:713–714
Veale DJ, Ritchlin C, Fitzgerald O (2005) Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 64(Suppl II,ii):26–29
Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289:1504–1548
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Borman, P., Babaoğlu, S., Gur, G. et al. Bone mineral density and bone turnover in patients with psoriatic arthritis. Clin Rheumatol 27, 443–447 (2008). https://doi.org/10.1007/s10067-007-0725-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-007-0725-8